Friday, November 16, 2012

• Cramer's Top Stock Picks: AMGN, HPY, but Avoid JCPat TheStreet (Fri, Nov 16)
• The Zacks Analyst Blog Highlights: Starbucks Corporation, Tevana Holdings, Inc., Celgene Corporation, Amgen Inc. and Pfizer Inc.Zacks (Fri, Nov 16)

Thursday, November 15, 2012

• Cramer's 'Mad Money' Recap: All Is Not Lostat TheStreet (Thu, Nov 15)
• Is Threshold on the Threshold?at Motley Fool (Thu, Nov 15)
• [video] Life of the Party?at CNBC (Thu, Nov 15)
• Celgene's Apremilast EncouragesZacks (Thu, Nov 15)
• AZN's Forxiga Gets EU ApprovalZacks (Thu, Nov 15)

Wednesday, November 14, 2012

• Supreme Court Could Impose New Restrictions On Class Actionsat Forbes (Wed, Nov 14)

Monday, November 12, 2012

• 2 Reasons You Should Love This Biotech's Good Newsat Motley Fool (Mon, Nov 12)
• Three Dividend Stocks That Will Fetch High Yieldsat Motley Fool (Mon, Nov 12)
• Upcoming Melanoma Conference Is An Excellent Source Of Small Pharma Investor Informationat Seeking Alpha (Mon, Nov 12)
• 5 Stocks Pushing The Health Care Sector Higherat TheStreet (Mon, Nov 12)
• Amgen Stock To Go Ex-dividend Tomorrow (AMGN)at TheStreet (Mon, Nov 12)

Friday, November 9, 2012

• Amgen About To Put More Money In Your Pocketat Forbes (Fri, Nov 9)
• Amgen initiated with a Neutral at Guggenheimtheflyonthewall.com (Fri, Nov 9)

Thursday, November 8, 2012

• Pfizer Loses Its Cash Cow!at Motley Fool (Thu, Nov 8)
• Obama Win Exposes Medical Stocks to QE Fatigueat TheStreet (Thu, Nov 8)
• These 3 Stocks Could Be Tomorrow's High-Yieldersat Seeking Alpha (Thu, Nov 8)

Wednesday, November 7, 2012

• A Blockbuster in the Makingat Motley Fool (Wed, Nov 7)
• How Safe Is Amgen's Dividend?at Seeking Alpha (Wed, Nov 7)
• Analyst Trims Vivus Target and 4 Stock Analyses Making Roundsat Wall St. Cheat Sheet (Wed, Nov 7)
• Pipelines, Low Multiples to Drive BioPharma Outperformanceat Motley Fool (Wed, Nov 7)

Tuesday, November 6, 2012

• Drug Firms Race To Reduce LDL, Novo Nordisk Awaits FDA Vote: Healthcare Business Recapat Wall St. Cheat Sheet (Tue, Nov 6)
• Xeljanz, A Cheaper-But-Expensive $25,000-A-Year Pfizer Pill For Rheumatoid Arthritis, Gets FDA Green Lightat Forbes (Tue, Nov 6)
• Amgen Inc (AMGN): Today's Featured Drugs Winnerat TheStreet (Tue, Nov 6)

Add AMGN News to My Yahoo!